BMS and Moffitt Cancer Center Enter Into a Collaboration Agreement
News Oct 03, 2015
Bristol-Myers Squibb Company and Moffitt Cancer Center have announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
As part of the I-O RPM program, Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists.
“Moffitt Cancer Center has had a long-standing commitment to immuno-oncology research, including in partnership with Bristol-Myers Squibb, and we look forward to our continued work with them as part of the I-O RPM program,” said Laura Bessen, MD, head of U.S. Medical, Bristol-Myers Squibb.
“This new partnership with Bristol-Myers Squibb will foster new Moffitt investigator-initiated studies for rare tumors and gives our faculty the opportunity to educate research students about innovative clinical trials,” said Dan Sullivan, M.D., Associate Center Director for Clinical Science at Moffitt.
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE